schizophrenia

Neumora's schizophrenia drug faces FDA hold over convulsions in rabbits
Fierce Biotech
Mon, 04/15/24 - 11:00 am
Neumora Therapeutics
schizophrenia
FDA
clinical trials
NMRA-266
Psychiatry drugs finally have pharma’s attention. Can they keep it?
BioPharma Dive
Tue, 04/9/24 - 05:50 pm
Karuna Therapeutics
schizophrenia
psychiatric disease
Bristol Myers' schizophrenia drug reduces symptoms without weight gain in late-stage studies
Reuters
Sun, 04/7/24 - 04:42 pm
Bristol Myers Squibb
schizophrenia
clinical trials
KarXT
Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
Reuters
Mon, 04/1/24 - 12:04 pm
Teva Pharmaceutical
JNJ
Viatris
schizophrenia
patents
Invega Sustenna
Acadia’s schizophrenia drug trial fails to meet primary endpoint
Clinical Trials Arena
Tue, 03/12/24 - 11:20 am
Acadia Pharmaceuticals
clinical trials
schizophrenia
pimavanserin
Acadia Pharmaceuticals' schizophrenia drug fails in late-stage study
Reuters
Mon, 03/11/24 - 04:56 pm
Acadia Pharma
antipsychotics
clinical trials
schizophrenia
Boehringer licenses Sosei schizophrenia drugs in €755m deal
Pharmaphorum
Mon, 03/11/24 - 11:40 am
Boehringer Ingelheim
schizophrenia
Sosei
Minerva schizophrenia drug rejected by FDA
BioPharma Dive
Tue, 02/27/24 - 11:17 pm
Minerva
schizophrenia
FDA
roluperidone
With good news on Lybalvi, Alkermes sees 10% share price increase
Fierce Pharma
Fri, 02/16/24 - 11:21 am
Alkermes
Lybalvi
schizophrenia
biopolar disorder
Karuna, Cerevel might be just the start of psychiatry drug M&A
BioPharma Dive
Tue, 01/23/24 - 11:17 am
M&A
Karuna Therapeutics
Cerevel Therapeutics
schizophrenia
AbbVie
Bristol Myers Squibb
5 FDA Decisions to Watch in Q1
BioSpace
Tue, 01/2/24 - 11:24 am
FDA
Iovance Biotherapeutics
melanoma
lifileucel
Minerva Neurosciences
schizophrenia
roluperidone
Viatris
Mapi Pharma
MS
multiple sclerosis
GA Depot
Madrigal Pharmaceuticals
NASH
resmetirom
Vertex Pharmaceuticals
CRISPR Therapeutics
exa-cel
beta thalassemia
Bristol Myers to acquire brain drug developer Karuna for $14B
BioPharma Dive
Fri, 12/22/23 - 09:44 am
Bristol Myers Squibb
Karuna Therapeutics
schizophrenia
M&A
KarXT
FDA kicks off review of Karuna’s schizophrenia drug KarXT
Pharmaphorum
Wed, 11/29/23 - 11:57 am
Karuna
KarXT
FDA
schizophrenia
Karuna keeps $6B sales forecast alive with blood pressure data on schizophrenia drug
Fierce Biotech
Fri, 11/17/23 - 11:31 am
Karuna Therapeutics
KarXT
blood pressure
schizophrenia
Reviva Pharmaceuticals reports data from schizophrenia drug trial
Clinical Trials Arena
Tue, 10/31/23 - 10:04 am
Reviva
brilaroxazine
clinical trials
schizophrenia
A brain-focused biotech raises $225M to develop drugs for schizophrenia, Parkinson’s
BioPharma Dive
Mon, 10/30/23 - 08:21 pm
Maplight Therapeutics
funding
schizophrenia
Reviva Pharma's schizophrenia drug succeeds in late-stage study
Reuters
Mon, 10/30/23 - 11:48 am
Reviva
schizophrenia
clinical trials
brilaroxazine
Newron's Schizophrenia Candidate Scores Mid-Stage Win, Moves to Phase III
BioSpace
Tue, 10/10/23 - 10:11 am
Newron Pharma
clinical trials
evenamide
schizophrenia
Karuna submits schizophrenia drug for US approval
BioPharma Dive
Thu, 09/28/23 - 12:02 pm
Karuna Therapeutics
KarXT
schizophrenia
FDA
Gilead-backed Lyndra Therapeutics cuts nearly a quarter of staff as ph. 3 data nears
Fierce Pharma
Sun, 09/17/23 - 09:16 pm
Lyndra Therapeutics
layoffs
schizophrenia
Risperidone

Pages